Adaptimmune Therapeutics PLC (ADAP)
0.8246
+0.02
(+3.10%)
USD |
NASDAQ |
Nov 04, 16:00
0.8246
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Shareholders Equity (Quarterly): 96.27M for June 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 96.27M |
| March 31, 2024 | 24.38M |
| December 31, 2023 | 39.51M |
| September 30, 2023 | 88.13M |
| June 30, 2023 | 126.65M |
| March 31, 2023 | 83.88M |
| December 31, 2022 | 81.88M |
| September 30, 2022 | 113.34M |
| June 30, 2022 | 141.92M |
| March 31, 2022 | 163.14M |
| December 31, 2021 | 205.96M |
| September 30, 2021 | 240.98M |
| June 30, 2021 | 277.94M |
| March 31, 2021 | 309.16M |
| December 31, 2020 | 341.23M |
| September 30, 2020 | 376.21M |
| June 30, 2020 | 407.58M |
| March 31, 2020 | 186.04M |
| December 31, 2019 | 123.64M |
| Date | Value |
|---|---|
| September 30, 2019 | 147.68M |
| June 30, 2019 | 186.99M |
| March 31, 2019 | 219.66M |
| December 31, 2018 | 246.88M |
| September 30, 2018 | 276.16M |
| June 30, 2018 | 165.10M |
| March 31, 2018 | 191.26M |
| December 31, 2017 | 202.98M |
| September 30, 2017 | 228.98M |
| June 30, 2017 | 229.50M |
| March 31, 2017 | 208.33M |
| December 31, 2016 | 166.14M |
| September 30, 2016 | 180.00M |
| June 30, 2016 | 196.99M |
| March 31, 2016 | 218.95M |
| September 30, 2015 | 250.68M |
| December 31, 2014 | 91.86M |
| June 30, 2014 | 2.41M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
24.38M
Minimum
Mar 2024
407.58M
Maximum
Jun 2020
180.41M
Average
141.92M
Median
Jun 2022
Shareholders Equity (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | 11.04M |
| Verona Pharma PLC | 168.27M |
| NuCana PLC | 4.806M |
| Autolus Therapeutics PLC | 527.84M |
| Bicycle Therapeutics PLC | 831.03M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 321.70M |
| Total Liabilities (Quarterly) | 225.43M |
| Debt to Equity Ratio | 0.2592 |
| Current Ratio | 3.092 |
| Net Debt Paydown Yield | -2.00% |